David Bredt - 17 Feb 2026 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Role
Chief Scientific Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
RAPP
Transactions as of
17 Feb 2026
Net transactions value
-$235,855
Form type
4
Filing time
19 Feb 2026, 19:05:23 UTC
Previous filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bredt David Chief Scientific Officer RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON /s/ Troy Ignelzi, Attorney-in-Fact 19 Feb 2026 0002022087

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RAPP Common Stock Sale $25,219 -900 -0.23% $28.02 394,675 17 Feb 2026 Direct F1, F2
transaction RAPP Common Stock Sale $156,328 -5,400 -1.4% $28.95 389,275 17 Feb 2026 Direct F1, F3
transaction RAPP Common Stock Sale $65,108 -2,200 -0.57% $29.59 387,075 17 Feb 2026 Direct F1, F4
transaction RAPP Common Stock Options Exercise $10,800 +6,000 +1.6% $1.80 393,075 19 Feb 2026 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RAPP Stock Options (Right to Buy) Options Exercise $0 -6,000 -6.4% $0.000000 88,080 19 Feb 2026 Common Stock 6,000 $1.80 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F5 Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction.
F6 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.